Next-generation CAR-T designs that could transform cancer treatment
“CAR T-cell therapy has emerged as a particularly promising cancer-specific treatment strategy”
2026-02-25
(Press-News.org)
“CAR T-cell therapy has emerged as a particularly promising cancer-specific treatment strategy.”
BUFFALO, NY – February 25, 2026 – A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.”
Led by Uzma Saqib — with corresponding author Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya — the perspective reviews recent clinical and translational advances in chimeric antigen receptor T-cell (CAR-T) therapy and highlights both its promise and its remaining barriers. The piece synthesizes recent clinical advances in hematologic malignancies and emerging applications in solid tumors, while focusing attention on safety (for example, cytokine release syndrome and neurotoxicity), resistance, antigen specificity, and access disparities.
The authors summarize the CAR-T workflow (leukapheresis → genetic modification and expansion → infusion) and note major recent clinical gains — including improved outcomes in leukemia, lymphoma, and multiple myeloma — that support wider adoption of cellular immunotherapy approaches. They emphasize that despite these advances, important clinical challenges remain, particularly for solid tumors, where antigen selection, tumor microenvironment, and T-cell trafficking limit efficacy. At the same time, the perspective highlights technological and clinical strategies under development to overcome these obstacles, including next-generation CAR designs and improved supportive-care protocols.
“Despite its promise, CAR T-cell therapy faces several critical challenges.”
The authors call out clear next steps for the field: (1) continued refinement of CAR constructs (dual-targeting, switchable/on-off systems, armored CARs) to improve specificity and reduce on-target/off-tumor toxicity; (2) improved management protocols and prophylactic measures to mitigate CRS and neurotoxicity; (3) expanded investigation of allogeneic or alternative CAR-T platforms to address manufacturing, cost, and access barriers; and (4) focused translational studies to improve T-cell trafficking and efficacy in solid tumors. They also highlight equity issues — socioeconomic and racial disparities that limit access to CAR-T — and urge that broad deployment plans include strategies to expand availability and affordability.
DOI: https://doi.org/10.18632/oncotarget.28836
Correspondence to: Krishnan Hajela – hajelak@gmail.com
Abstract video: https://www.youtube.com/watch?v=T4hbwPToVKI
Keywords: CAR-T therapy, cancer, therapeutic approaches
Click here to sign up for free Altmetric alerts about this article.
________
About Oncotarget:
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
END
ELSE PRESS RELEASES FROM THIS DATE:
2026-02-25
Patients are now expected to navigate much of their care online — from seeing their doctor on a screen to booking appointments, refilling prescriptions, and checking test results through health care portals.
Yet, according to a new study by UC San Francisco, most health systems are skipping a crucial step: asking whether their patients have the access and skills to use these digital tools.
The researchers surveyed nearly 150 clinicians and informatics leaders from health care systems across the country during the first half of 2024. Just 44% said they asked their patients if they could use digital devices. Among the ...
2026-02-25
Background and objectives
Endometrial polyp (EMP) is one of the most common diagnoses in the evaluation of women with abnormal uterine bleeding. Understanding the malignancy risk associated with EMPs and related risk factors is essential for guiding both pathology practice and clinical management. This study aimed to explore risk factors for malignancy in EMPs.
Methods
The pathology database was searched for women diagnosed with EMP between 2021 and 2022. Patient age, polyp size, background endometrium, recurrence, and (if applicable) cancer types were recorded. Immunohistochemistry (IHC) for p53 and p16 was performed on selected cases. Risk factors for malignancy were analyzed using Chi-square ...
2026-02-25
WEST LAFAYETTE, Ind. and MIAMI — Gibson Oncology, a clinical-stage private pharmaceutical company headquartered in Miami, announced it has entered Phase 2 clinical trials with LMP744 for the treatment of first-time recurrent glioblastoma patients.
The company is focused on advancing its novel small molecules with dual-action inhibition of topoisomerase 1 and reduction of overexpression of the cMYC oncogene.
“The primary endpoint of the study is to evaluate tumor regression in patients with recurrent glioblastoma. Secondary endpoints will evaluate parameters such as progression-free survival, biological changes in glioblastoma tissues obtained pre- and post-treatment, ...
2026-02-25
Photocatalysts facilitate chemical reactions by absorbing light. Metal-based photocatalysts are widely used in organic synthesis due to their durability and the ability to tune their function by modifying the ligands attached to the central metal atom.
Most metals used in photocatalysts, such as ruthenium and iridium, are rare and expensive. Researchers at Nagoya University, Japan, previously developed an iron-based alternative, but it required large amounts of costly chiral ligands, which act as spatial ...
2026-02-25
When researchers studied Norwegians who thought tick bites caused their chronic health problems, they found no objective evidence linking the symptoms to ticks.
The same study finds that health problems reported by participants were associated with little physical activity and low labour force participation.
Many Norwegians pull ticks from their bodies every single summer. Roughly 2 per cent of those who are bitten are infected by a bacterium that leads to Lyme disease.
The disease can start with a rash that eventually spreads in the skin with a ring-shaped pattern. In some people, the disease can develop into facial paralysis, meningitis or other ...
2026-02-25
An advanced detection system to identify and trace blockchain funds connected with criminal activity has been presented today at the Annual CyberASAP Demo Day in London.
The system, called SynapTrack, enables faster and more accurate detection of fraudulent activity using blockchains and cryptocurrencies, where traditional anti-money laundering and counter-terrorist financing systems struggle to keep pace.
Although current fraud detection methods pick up unusual activity, they deliver an extremely high rate (40%) of false positive reports. These require manual checking by compliance professionals, resulting in backlogs in identifying and acting ...
2026-02-25
Background and objectives
Infectious diarrhea is a gastrointestinal illness that results in around 1.7 billion cases and 525,000 deaths annually, particularly among children under five, according to the World Health Organization. While some Cameroonian medicinal plants show promise for treating diarrhea, many plants are used without established scientific evidence of their efficacy. These plants include Tithonia diversifolia (T. diversifolia) and Solanum torvum (S. torvum), which are traditionally used to treat diarrheal symptoms. This study sought to investigate the anti-Shigella activity of leaf ...
2026-02-25
BETHESDA, MD – February 25, 2026 | The ACMG Foundation for Genetic and Genomic Medicine (ACMGF), in partnership with Genetics in Medicine Open (GIM Open), is pleased to announce Qiliang (Andy) Ding, PhD, as the inaugural recipient of the 2026 Rising Scholar Trainee Award. This new annual award recognizes the most outstanding research publication by a trainee published in Genetics in Medicine Open during the preceding calendar year.
The Rising Scholar Trainee Award was established to support early-career investigators and to recognize high-quality scholarly contributions in medical genetics and genomics. Eligible individuals include ...
2026-02-25
The Korea Research Institute of Standards and Science (KRISS, President Lee Ho Seong) has developed a next-generation gas sensor technology that uses low-cost and safe LED light to precisely distinguish multiple hazardous gases. Compared with conventional sensors that operate at high temperatures, the new technology consumes significantly less power, offering greater cost efficiency while delivering broad applicability. It is expected to enhance gas safety across industrial settings as well as everyday environments.
Gas sensors currently used in industrial ...
2026-02-25
PULLMAN, Wash. — Promoting women’s ownership in wineries can boost sales among the largest group of U.S. wine consumers, who happen to be women.
Messages like “proudly made by a woman winemaker” increased women’s intentions of purchasing wines, particularly when the label’s artwork reinforced the point with feminine gender cues such as flowers. Women were also willing to pay higher prices for those wines, according to the research from Washington State University and Auburn University.
The findings are noteworthy because 59% of all wine purchases in the United States are made ...
LAST 30 PRESS RELEASES:
[Press-News.org] Next-generation CAR-T designs that could transform cancer treatment
“CAR T-cell therapy has emerged as a particularly promising cancer-specific treatment strategy”
